Medpace Holdings, Inc. (MEDP) Form 8-K — Oct 21, 2026
$MEDPForm 8-KItems 2.02, 8.01, 9.01Filed Oct 21, 2026, 4:15 PM ET0001668397-26-000034Original filing
Medpace reported Q3 2026 revenue of $716.0 million, up 8.5% year over year, with GAAP net income of $137.5 million or $4.84 per diluted share, up from $3.86 a year ago. Net income margin expanded to 19.2% from 16.8%, and EBITDA grew 16.0% to $172.1 million, a 24.0% margin. Backlog rose 5.6% to $3,167.2 million and net new business awards grew 10.6% to $873.4 million, supporting the company's updated FY2026 guidance of $2.835-$2.855 billion in revenue and $17.97-$18.32 in diluted EPS.
Key figures
- Eps
- 4.84
- Revenue
- 716000000
- Guidance
- FY2026 revenue $2.835B-$2.855B (12.0%-12.8% growth); GAAP net income $514.0M-$524.0M; EBITDA $638.0M-$652.0M; diluted EPS $17.97-$18.32
- Net Income
- 137500000
- Revenue Yoy
- 8.5%
- Total Assets
- 2302595000
- Cash Position
- 705315000
- Shares Outstanding
- 27966686
- Ytd revenue
- 2129935000
- Backlog growth
- 5.6%
- Ebitda q3 2026
- 172137000
- Ytd revenue growth
- 16.9%
- Ebitda margin q3 2026
- 24.0%
- Backlog conversion rate
- 23.8%
- Net new business awards
- 873400000
- Prior buyback remaining
- 527000000
- New buyback authorization
- $1.0 billion through December 31, 2028
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.